SGLT2 inhibitors such as dapagliflozin and empagliflozin are associated with improved outcomes among many heart failure patients. The medications are not cost-effective, however, limiting their overall value. Read the full economic analysis to learn more. 

Catch up on the biggest news that came out of the second day of ACC.23 in New Orleans. 

Read our monthly recap of FDA-related news items from the world of cardiovascular medicine. 

Scientists were able to identify a total of 21 genes linked to cardiovascular conditions such as AFib and heart failure.

Reviewing data from several studies, researchers wrote that vericiguat (Verquvo) could potentially "become a breakthrough in the treatment of heart failure." 

The move represents a return of sorts for Pinney, who served Mount Sinai in a variety of leadership roles from 2004 to 2020.